Search Results

Analysis of COURAGE Crossover Patients Supports an Initial Trial of Optimal Medical Therapy for Stable Ischemic Heart Disease

July 9, 2013—An analysis of the frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy (OMT) in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial was published by John A. Spertus, MD, et al on behalf of the COURAGE trial investigators and coordinators in Circulation: Cardiovascular Quality and Outcomes (2013;6:409–418).

ISCHEMIA Provides Clarity on Invasive Strategies Versus Medical Therapy to Manage Higher-Risk Patients With Stable Ischemic Heart Disease

November 16, 2019—At the American Heart Association (AHA) scientific sessions 2019, held November 16–18 in Philadelphia, Pennsylvania, Judith S. Hochman, MD, presented findings from the ISCHEMIA trial, which sought to determine the best management strategy for higher-risk patients with stable ischemic heart disease and moderate to severe ischemia on stress testing. John A. Spertus, MD, then presented the quality-of-life (QOL) findings from the ISCHEMIA trial.

Terumo’s ePrism Platform Studied for AKI Prevention During Coronary Angiography

November 9, 2022—Terumo Medical Corporation recently announced the publication of a study demonstrating that patients at high risk for acute kidney injury (AKI), the most common complication of percutaneous coronary intervention (PCI), had a significant reduction in AKI when cardiologists used Terumo Health Outcomes’ (THO) ePrism clinical decision support (CDS) software platform.